Shanghai YingLi Pharmaceutical Co. Ltd.
Works in GI & liver · Hematology · Immunology · Metabolic & endocrine · Oncology
Shanghai YingLi Pharmaceutical Co. Ltd. is a clinical trial sponsor. It has 5 active clinical trials with 956 planned participants, across 5 therapeutic areas. Since 2021 it has completed 1 trial and stopped 0 early.
Trial track record · since 2021
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Shanghai YingLi Pharmaceutical Co. Ltd
Shanghai YingLi Pharmaceutical Co. Ltd is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 956 planned participants, in GI & liver, Hematology, Immunology, Metabolic & endocrine and other areas. Since 2021 it has completed 1 trial and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Shanghai YingLi Pharmaceutical Co. Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2025-04-09.
Approve Suite is not affiliated with Shanghai YingLi Pharmaceutical Co. Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.